Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v3.21.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated deficit
Preferred A Shares (pre-merger - BiomX Ltd.),
Preferred B Shares (pre-merger - BiomX Ltd.),
Total
Balance at Dec. 31, 2018 [1] $ 64,410 $ (21,609) $ 1 $ 1 $ 42,803
Balance, shares at Dec. 31, 2018 2,307,871     7,543,831 5,170,357  
Acquisition of treasury stock [1] (19) (19)
Acquisition of treasury stock, shares (5,700)          
Issuance of shares [2] 1,800 [1] 1,800
Issuance of shares, shares [2]     308,628  
Effect of Recapitalization Transaction $ 2 59,397 $ (1) $ (1) 59,397
Effect of Recapitalization Transaction, shares 20,486,082     (7,543,831) (5,478,985)  
Stock-based payment   938     938
Exercise of stock options [1] 100     100
Exercise of stock options, shares 74,582          
Net loss     (20,563)     (20,563)
Balance at Dec. 31, 2019 $ 2 126,626 (42,172)     84,456
Balance, shares at Dec. 31, 2019 22,862,835          
Issuance of Common Stock under Open Market Sales Agreement [3] (98)     (98)
Issuance of Common Stock under Open Market Sales Agreement, shares [3] 10,176          
Stock-based payment   2,890     2,890
Exercise of stock options 307     307
Exercise of stock options, shares 391,626          
Net loss     (30,086)     (30,086)
Balance at Dec. 31, 2020 $ 2 $ 129,725 $ (72,258)     $ 57,469
Balance, shares at Dec. 31, 2020 23,264,637          
[1] Less than $1.
[2] Net of issuance expenses of $114. Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction (refer to Note 1).
[3] Net of issuance expenses of $158.